Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598806 · ClinicalTrials.gov registry record · Phase 3
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
A Phase 3 study of Bladder Cancer, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 812
- Enrollment target
- 20
- Study locations
NCT00598806: Completed Phase 3 study of Bladder Cancer, sponsored by Spectrum Pharmaceuticals.
NCT00598806 is a Phase 3 study of Bladder Cancer that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 812 participants, below the 12,749-participant average among 175 other Bladder Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00598806, a Phase 3 study of Bladder Cancer, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 812 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.
Primary Outcome
The percentage of participants with histologically confirmed recurrence of the bladder tumor at any time after randomization and on or before year 2.
Conditions Studied
Interventions
- DRUG Placebo
- PROCEDURE TURBT
- DRUG Apaziquone
Study Locations (20)
New York
- Medical & Clinical Research Associates, LLC - Bay Shore
- Urology Associates, PC - Manhasset
- North Shore - LIJ Health System - The Arthur Smith Institute for Urology - New Hyde Park
Georgia
- Urology Enterprises - Marietta
- North Fulton Urology - Roswell
Maryland
- Chesapeake Urology Research Associates - Baltimore
- Chesapeake Urology Research Associates - Towson
New Jersey
- PharmaTrials, Inc. - Male & Female Urology - Hillsborough
- PharmaTrials, Inc. - Hillsborough
North Carolina
- Alliance Urology Specialists - Greensboro
- Piedmont Medical Research - Winston-Salem
California
- Advanced Urology Medical Center Clinical Trials - Anaheim
Florida
- Hal J. Bashein, D.O. - West Palm Beach
Illinois
- Hines VA Hospital - Hines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 812 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
What the finished NCT00598806 record still lists
NCT00598806 is an interventional study that assigns participants to a tested intervention. The registered 812 participants enrollment target is mid-sized for trials with a published cap, below the 12,749-participant average among 175 other Bladder Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00598806 names 20 study sites across 14 states, led by New York, Georgia, Maryland.
Frequently Asked Questions
What is clinical trial NCT00598806 about?
NCT00598806 is a clinical study titled "Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)". The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.
What is the current status of trial NCT00598806?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 812 participants. The study started on 2007-08. Estimated completion is 2012-01.
What conditions does trial NCT00598806 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT00598806?
The interventions under investigation include: Placebo (DRUG), TURBT (PROCEDURE), Apaziquone (DRUG).
Who is sponsoring clinical trial NCT00598806?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00598806 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00598806's enrollment target sits among peer trials
812 21st of 175 higher than 155 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
RECRUITING · Phase 3
-
A Study of Surgical Techniques During Cystectomy
RECRUITING · Phase 3
-
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
RECRUITING · Phase 3
-
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia